Human T-lymphotropic virus type 1 (HTLV-1): Persistence and immune control
Human T-lymphotropic virus type 1 (HTLV-1): Persistence and immune control
复制标题
DOI：
10.1007/bf02983553
复制
发表时间：
2003-11-01
影响因子：
2.1
通讯作者：
Bangham, CRM
中科院分区：
文献类型：
--
作者：
Bangham, CRM
人类逆转录病毒人类嗜T淋巴细胞病毒1型（HTLV-1）与两种不同类型的疾病相关：称为成人T细胞白血病的恶性肿瘤和一系列慢性炎症性疾病，包括中枢神经系统疾病HTLV-1相关的脊髓病/热带痉挛性截瘫（HAM/TSP）。直到最近，人们才相信HTLV-1在体内大部分是潜伏的。然而，来自许多类型的实验的证据表明，HTLV-1持续表达其基因，并且个体的HTLV-1前病毒载量的“设定点”主要由该个体对病毒的细胞免疫应答的效率决定。这些结论有两个主要后果。首先，HTLV-1可能易受抗逆转录病毒药物治疗或免疫治疗的影响。第二，HTLV-1感染已成为分析抗病毒免疫应答效率的决定因素的有用系统。(C)2003年日本血液学会。
The human retrovirus human T-lymphotropic virus type 1 (HTLV-1) is associated with two distinct types of disease: the malignancy known as adult T-cell leukemia and a range of chronic inflammatory conditions including the central nervous system disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Until recently, it was believed that HTLV-1 was largely latent in vivo. However, evidence from a number of types of experiments shows that HTLV-1 persistently expresses its genes, and that the "set point" of an individual's proviral load of HTLV-1 is mainly determined by the efficiency of that individual's cellular immune response to the virus. These conclusions have two main consequences. First, HTLV-1 may be vulnerable to antiretroviral drug therapy or immunotherapy. Second, HTLV-1 infection has become a useful system to analyze the determinants of the efficiency of the antiviral immune response. (C) 2003 The Japanese Society of Hematology.